Genevoyager key facts
- Developer of biopharmaceutical development and production systems designed for gene therapy and vaccine research purposes.
- It has raised $27.9M.
- Notable investors include Wuhan Hi-Tech, Wuhan Huagong Venture Capital, Haide Zeguang Investment, Homsun Capital, SDIC Venture Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Genevoyager: the Monday email on marks, rounds and moves
Genevoyager funding rounds
No funding rounds for Genevoyager are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Genevoyager investors
8 investors are on record for Genevoyager, including Wuhan Hi-Tech, Wuhan Huagong Venture Capital, Haide Zeguang Investment and Homsun Capital.
About Genevoyager
Developer of biopharmaceutical development and production systems designed for gene therapy and vaccine research purposes. The company offers large-scale AAV vector preparation technology, cGMP-compliant protein and viral vector manufacturing facilities, integrated CRO/CDMO services, proprietary recombinant bacmid systems for stable yield, liver-specific gene expression promoters, and advanced quality control workflows, thereby enabling biotechnology firms and clinical research organizations to accelerate therapeutic development, ensure regulatory compliance, improve production scalability, and support innovative treatments for genetic disorders and protein-based therapies.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2022
- Employees
- 300
- Website
- genevoyager.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Genevoyager doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.